Kalvista Pharmaceuticals, Inc. (KALV) SEC Filings — 2025
13 SEC filings for Kalvista Pharmaceuticals, Inc. (KALV) in 2025.
Filings
- KalVista Posts First EKTERLY Revenue, Losses Widen Amid Launch Costs — 10-Q · Nov 10, 2025
- KalVista Pharmaceuticals Files 8-K on Officer/Director Changes — 8-K · Oct 6, 2025
- KalVista Pharmaceuticals Files 8-K: Director Changes & Officer Compensation Updates — 8-K · Oct 2, 2025
- KalVista Pharmaceuticals Files 8-K on Agreements and Equity Sales — 8-K · Sep 29, 2025
- KalVista's EKTERLY Launch Drives Revenue, But Losses Widen to $60M — 10-Q · Sep 11, 2025
- KalVista Pharmaceuticals, Inc. Files 8-K — 8-K · Aug 21, 2025
- KalVista Pharmaceuticals Files 8-K on Financials — 8-K · Jul 10, 2025
- KalVista's Net Loss Widens to $120.5M Amid Sebetralstat Push — 10-K · Jul 10, 2025
- KalVista Pharmaceuticals Files 8-K Report — 8-K · Jul 7, 2025
- KalVista Pharmaceuticals Announces Board and Compensation Changes — 8-K · May 12, 2025
- KalVista Pharmaceuticals Files 8-K with Material Agreement Details — 8-K · Apr 8, 2025
- KalVista Pharmaceuticals Changes Fiscal Year End — 8-K · Mar 17, 2025
- KalVista Pharmaceuticals Files 10-Q — 10-Q · Mar 12, 2025